La Comisión Europea ha aprobado el fármaco 'JEMPERLI' (dostarlimab), de GSK, en combinación con la quimioterapia estándar ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

Esta ampliación de dostarlimab, de GSK, incluye los tumores MMRp/MSS, que representan aproximadamente el 75% de los casos de ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

Redacción MSD presenta resultados positivos de un anticuerpo en investigación para virus respiratorio sincitial Merck Sharp & ...

(Alliance News) - GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemotherapy, to include all adult patients with primary advanced or ...

GSK (GSK) and the University of Oxford announced that they have entered a new research collaboration focused on the potential of cancer ...

GSK (NYSE:GSK) announced Tuesday that the EU drug regulator has agreed to review depemokimab, an experimental monoclonal antibody targeting a class of cell signaling molecules called interleukin-5, ...